Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC–MS/MS with electrospray ionization: Assay development, validation and application to a clinical study

This publication has 22 references indexed in Scilit:

• Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers
  Clinical Therapeutics, 2003
• A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers
  Clinical Therapeutics, 2003
• Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)
  The American Journal of Cardiology, 2003
• Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment
  European Journal of Clinical Pharmacology, 2003
• Rosuvastatin: A Highly Effective New HMG‐CoA Reductase Inhibitor
  Cardiovascular Drug Reviews, 2002
• Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial
  American Heart Journal, 2002
• Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers
  British Journal of Clinical Pharmacology, 2002
• No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor
  The Journal of Clinical Pharmacology, 2002
• Fibrates, dyslipoproteinaemia and cardiovascular disease
  Current Opinion in Lipidology, 1999
• Micronised fenofibrate
  Atherosclerosis, 1994